The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Leuprolide Market Research Report 2025
Synopsis
Leuprolide belongs to the general class of drugs known as hormones or hormone antagonists. It is a synthetic 9 residue peptide analog of gonadotropin releasing hormone. Leuprolide is used to treat advanced prostate cancer. It is also used to treat uterine fibroids and endometriosis. Leuprolide is also under investigation for possible use in the treatment of mild to moderate Alzheimer's disease.
The global Leuprolide market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Leuprolide is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Leuprolide is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Leuprolide in Breast Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Leuprolide include TOLMAR PHARMACEUTICALS, Sanofi, Teva, Sandoz (Novartis), Sun Pharmaceutical, AbbVie, Bayer, Takeda and Beijing Boente Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Leuprolide, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Leuprolide.
Report Scope
The Leuprolide market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Leuprolide market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Leuprolide companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
TOLMAR PHARMACEUTICALS
Sanofi
Teva
Sandoz (Novartis)
Sun Pharmaceutical
AbbVie
Bayer
Takeda
Beijing Boente Pharmaceutical
Livzon Pharmaceutical
Selleck
Hangzhou Peptide Biochemical
Chengdu Shenguo Biological Pharmaceutical
SciAnda Pharma
Daewoong
GP Pharm
Enteris BioPharma
Chong Kun Dang
Leadiant Biosciences
Hikma Pharmaceuticals
Lee Pharma
Hanall
Segment by Type
Subcutaneous
Topical
Segment by Application
Breast Cancer
Endometriosis
Precocious Puberty
Prostate Cancer
Uterine Fibrosis
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Leuprolide companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Leuprolide belongs to the general class of drugs known as hormones or hormone antagonists. It is a synthetic 9 residue peptide analog of gonadotropin releasing hormone. Leuprolide is used to treat advanced prostate cancer. It is also used to treat uterine fibroids and endometriosis. Leuprolide is also under investigation for possible use in the treatment of mild to moderate Alzheimer's disease.
The global Leuprolide market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Leuprolide is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Leuprolide is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Leuprolide in Breast Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Leuprolide include TOLMAR PHARMACEUTICALS, Sanofi, Teva, Sandoz (Novartis), Sun Pharmaceutical, AbbVie, Bayer, Takeda and Beijing Boente Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Leuprolide, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Leuprolide.
Report Scope
The Leuprolide market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Leuprolide market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Leuprolide companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
TOLMAR PHARMACEUTICALS
Sanofi
Teva
Sandoz (Novartis)
Sun Pharmaceutical
AbbVie
Bayer
Takeda
Beijing Boente Pharmaceutical
Livzon Pharmaceutical
Selleck
Hangzhou Peptide Biochemical
Chengdu Shenguo Biological Pharmaceutical
SciAnda Pharma
Daewoong
GP Pharm
Enteris BioPharma
Chong Kun Dang
Leadiant Biosciences
Hikma Pharmaceuticals
Lee Pharma
Hanall
Segment by Type
Subcutaneous
Topical
Segment by Application
Breast Cancer
Endometriosis
Precocious Puberty
Prostate Cancer
Uterine Fibrosis
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Leuprolide companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Leuprolide Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Subcutaneous
1.2.3 Topical
1.3 Market by Application
1.3.1 Global Leuprolide Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Breast Cancer
1.3.3 Endometriosis
1.3.4 Precocious Puberty
1.3.5 Prostate Cancer
1.3.6 Uterine Fibrosis
1.3.7 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Leuprolide Market Perspective (2019-2030)
2.2 Leuprolide Growth Trends by Region
2.2.1 Global Leuprolide Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Leuprolide Historic Market Size by Region (2019-2024)
2.2.3 Leuprolide Forecasted Market Size by Region (2025-2030)
2.3 Leuprolide Market Dynamics
2.3.1 Leuprolide Industry Trends
2.3.2 Leuprolide Market Drivers
2.3.3 Leuprolide Market Challenges
2.3.4 Leuprolide Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Leuprolide Players by Revenue
3.1.1 Global Top Leuprolide Players by Revenue (2019-2024)
3.1.2 Global Leuprolide Revenue Market Share by Players (2019-2024)
3.2 Global Leuprolide Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Leuprolide Revenue
3.4 Global Leuprolide Market Concentration Ratio
3.4.1 Global Leuprolide Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Leuprolide Revenue in 2023
3.5 Leuprolide Key Players Head office and Area Served
3.6 Key Players Leuprolide Product Solution and Service
3.7 Date of Enter into Leuprolide Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Leuprolide Breakdown Data by Type
4.1 Global Leuprolide Historic Market Size by Type (2019-2024)
4.2 Global Leuprolide Forecasted Market Size by Type (2025-2030)
5 Leuprolide Breakdown Data by Application
5.1 Global Leuprolide Historic Market Size by Application (2019-2024)
5.2 Global Leuprolide Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Leuprolide Market Size (2019-2030)
6.2 North America Leuprolide Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Leuprolide Market Size by Country (2019-2024)
6.4 North America Leuprolide Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Leuprolide Market Size (2019-2030)
7.2 Europe Leuprolide Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Leuprolide Market Size by Country (2019-2024)
7.4 Europe Leuprolide Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Leuprolide Market Size (2019-2030)
8.2 Asia-Pacific Leuprolide Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Leuprolide Market Size by Region (2019-2024)
8.4 Asia-Pacific Leuprolide Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Leuprolide Market Size (2019-2030)
9.2 Latin America Leuprolide Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Leuprolide Market Size by Country (2019-2024)
9.4 Latin America Leuprolide Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Leuprolide Market Size (2019-2030)
10.2 Middle East & Africa Leuprolide Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Leuprolide Market Size by Country (2019-2024)
10.4 Middle East & Africa Leuprolide Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 TOLMAR PHARMACEUTICALS
11.1.1 TOLMAR PHARMACEUTICALS Company Detail
11.1.2 TOLMAR PHARMACEUTICALS Business Overview
11.1.3 TOLMAR PHARMACEUTICALS Leuprolide Introduction
11.1.4 TOLMAR PHARMACEUTICALS Revenue in Leuprolide Business (2019-2024)
11.1.5 TOLMAR PHARMACEUTICALS Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Detail
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Leuprolide Introduction
11.2.4 Sanofi Revenue in Leuprolide Business (2019-2024)
11.2.5 Sanofi Recent Development
11.3 Teva
11.3.1 Teva Company Detail
11.3.2 Teva Business Overview
11.3.3 Teva Leuprolide Introduction
11.3.4 Teva Revenue in Leuprolide Business (2019-2024)
11.3.5 Teva Recent Development
11.4 Sandoz (Novartis)
11.4.1 Sandoz (Novartis) Company Detail
11.4.2 Sandoz (Novartis) Business Overview
11.4.3 Sandoz (Novartis) Leuprolide Introduction
11.4.4 Sandoz (Novartis) Revenue in Leuprolide Business (2019-2024)
11.4.5 Sandoz (Novartis) Recent Development
11.5 Sun Pharmaceutical
11.5.1 Sun Pharmaceutical Company Detail
11.5.2 Sun Pharmaceutical Business Overview
11.5.3 Sun Pharmaceutical Leuprolide Introduction
11.5.4 Sun Pharmaceutical Revenue in Leuprolide Business (2019-2024)
11.5.5 Sun Pharmaceutical Recent Development
11.6 AbbVie
11.6.1 AbbVie Company Detail
11.6.2 AbbVie Business Overview
11.6.3 AbbVie Leuprolide Introduction
11.6.4 AbbVie Revenue in Leuprolide Business (2019-2024)
11.6.5 AbbVie Recent Development
11.7 Bayer
11.7.1 Bayer Company Detail
11.7.2 Bayer Business Overview
11.7.3 Bayer Leuprolide Introduction
11.7.4 Bayer Revenue in Leuprolide Business (2019-2024)
11.7.5 Bayer Recent Development
11.8 Takeda
11.8.1 Takeda Company Detail
11.8.2 Takeda Business Overview
11.8.3 Takeda Leuprolide Introduction
11.8.4 Takeda Revenue in Leuprolide Business (2019-2024)
11.8.5 Takeda Recent Development
11.9 Beijing Boente Pharmaceutical
11.9.1 Beijing Boente Pharmaceutical Company Detail
11.9.2 Beijing Boente Pharmaceutical Business Overview
11.9.3 Beijing Boente Pharmaceutical Leuprolide Introduction
11.9.4 Beijing Boente Pharmaceutical Revenue in Leuprolide Business (2019-2024)
11.9.5 Beijing Boente Pharmaceutical Recent Development
11.10 Livzon Pharmaceutical
11.10.1 Livzon Pharmaceutical Company Detail
11.10.2 Livzon Pharmaceutical Business Overview
11.10.3 Livzon Pharmaceutical Leuprolide Introduction
11.10.4 Livzon Pharmaceutical Revenue in Leuprolide Business (2019-2024)
11.10.5 Livzon Pharmaceutical Recent Development
11.11 Selleck
11.11.1 Selleck Company Detail
11.11.2 Selleck Business Overview
11.11.3 Selleck Leuprolide Introduction
11.11.4 Selleck Revenue in Leuprolide Business (2019-2024)
11.11.5 Selleck Recent Development
11.12 Hangzhou Peptide Biochemical
11.12.1 Hangzhou Peptide Biochemical Company Detail
11.12.2 Hangzhou Peptide Biochemical Business Overview
11.12.3 Hangzhou Peptide Biochemical Leuprolide Introduction
11.12.4 Hangzhou Peptide Biochemical Revenue in Leuprolide Business (2019-2024)
11.12.5 Hangzhou Peptide Biochemical Recent Development
11.13 Chengdu Shenguo Biological Pharmaceutical
11.13.1 Chengdu Shenguo Biological Pharmaceutical Company Detail
11.13.2 Chengdu Shenguo Biological Pharmaceutical Business Overview
11.13.3 Chengdu Shenguo Biological Pharmaceutical Leuprolide Introduction
11.13.4 Chengdu Shenguo Biological Pharmaceutical Revenue in Leuprolide Business (2019-2024)
11.13.5 Chengdu Shenguo Biological Pharmaceutical Recent Development
11.14 SciAnda Pharma
11.14.1 SciAnda Pharma Company Detail
11.14.2 SciAnda Pharma Business Overview
11.14.3 SciAnda Pharma Leuprolide Introduction
11.14.4 SciAnda Pharma Revenue in Leuprolide Business (2019-2024)
11.14.5 SciAnda Pharma Recent Development
11.15 Daewoong
11.15.1 Daewoong Company Detail
11.15.2 Daewoong Business Overview
11.15.3 Daewoong Leuprolide Introduction
11.15.4 Daewoong Revenue in Leuprolide Business (2019-2024)
11.15.5 Daewoong Recent Development
11.16 GP Pharm
11.16.1 GP Pharm Company Detail
11.16.2 GP Pharm Business Overview
11.16.3 GP Pharm Leuprolide Introduction
11.16.4 GP Pharm Revenue in Leuprolide Business (2019-2024)
11.16.5 GP Pharm Recent Development
11.17 Enteris BioPharma
11.17.1 Enteris BioPharma Company Detail
11.17.2 Enteris BioPharma Business Overview
11.17.3 Enteris BioPharma Leuprolide Introduction
11.17.4 Enteris BioPharma Revenue in Leuprolide Business (2019-2024)
11.17.5 Enteris BioPharma Recent Development
11.18 Chong Kun Dang
11.18.1 Chong Kun Dang Company Detail
11.18.2 Chong Kun Dang Business Overview
11.18.3 Chong Kun Dang Leuprolide Introduction
11.18.4 Chong Kun Dang Revenue in Leuprolide Business (2019-2024)
11.18.5 Chong Kun Dang Recent Development
11.19 Leadiant Biosciences
11.19.1 Leadiant Biosciences Company Detail
11.19.2 Leadiant Biosciences Business Overview
11.19.3 Leadiant Biosciences Leuprolide Introduction
11.19.4 Leadiant Biosciences Revenue in Leuprolide Business (2019-2024)
11.19.5 Leadiant Biosciences Recent Development
11.20 Hikma Pharmaceuticals
11.20.1 Hikma Pharmaceuticals Company Detail
11.20.2 Hikma Pharmaceuticals Business Overview
11.20.3 Hikma Pharmaceuticals Leuprolide Introduction
11.20.4 Hikma Pharmaceuticals Revenue in Leuprolide Business (2019-2024)
11.20.5 Hikma Pharmaceuticals Recent Development
11.21 Lee Pharma
11.21.1 Lee Pharma Company Detail
11.21.2 Lee Pharma Business Overview
11.21.3 Lee Pharma Leuprolide Introduction
11.21.4 Lee Pharma Revenue in Leuprolide Business (2019-2024)
11.21.5 Lee Pharma Recent Development
11.22 Hanall
11.22.1 Hanall Company Detail
11.22.2 Hanall Business Overview
11.22.3 Hanall Leuprolide Introduction
11.22.4 Hanall Revenue in Leuprolide Business (2019-2024)
11.22.5 Hanall Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Leuprolide Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Subcutaneous
Table 3. Key Players of Topical
Table 4. Global Leuprolide Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Leuprolide Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Leuprolide Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Leuprolide Market Share by Region (2019-2024)
Table 8. Global Leuprolide Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Leuprolide Market Share by Region (2025-2030)
Table 10. Leuprolide Market Trends
Table 11. Leuprolide Market Drivers
Table 12. Leuprolide Market Challenges
Table 13. Leuprolide Market Restraints
Table 14. Global Leuprolide Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Leuprolide Market Share by Players (2019-2024)
Table 16. Global Top Leuprolide Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Leuprolide as of 2023)
Table 17. Ranking of Global Top Leuprolide Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Leuprolide Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Leuprolide Product Solution and Service
Table 21. Date of Enter into Leuprolide Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Leuprolide Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Leuprolide Revenue Market Share by Type (2019-2024)
Table 25. Global Leuprolide Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Leuprolide Revenue Market Share by Type (2025-2030)
Table 27. Global Leuprolide Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Leuprolide Revenue Market Share by Application (2019-2024)
Table 29. Global Leuprolide Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Leuprolide Revenue Market Share by Application (2025-2030)
Table 31. North America Leuprolide Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Leuprolide Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Leuprolide Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Leuprolide Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Leuprolide Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Leuprolide Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Leuprolide Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Leuprolide Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Leuprolide Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Leuprolide Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Leuprolide Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Leuprolide Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Leuprolide Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Leuprolide Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Leuprolide Market Size by Country (2025-2030) & (US$ Million)
Table 46. TOLMAR PHARMACEUTICALS Company Detail
Table 47. TOLMAR PHARMACEUTICALS Business Overview
Table 48. TOLMAR PHARMACEUTICALS Leuprolide Product
Table 49. TOLMAR PHARMACEUTICALS Revenue in Leuprolide Business (2019-2024) & (US$ Million)
Table 50. TOLMAR PHARMACEUTICALS Recent Development
Table 51. Sanofi Company Detail
Table 52. Sanofi Business Overview
Table 53. Sanofi Leuprolide Product
Table 54. Sanofi Revenue in Leuprolide Business (2019-2024) & (US$ Million)
Table 55. Sanofi Recent Development
Table 56. Teva Company Detail
Table 57. Teva Business Overview
Table 58. Teva Leuprolide Product
Table 59. Teva Revenue in Leuprolide Business (2019-2024) & (US$ Million)
Table 60. Teva Recent Development
Table 61. Sandoz (Novartis) Company Detail
Table 62. Sandoz (Novartis) Business Overview
Table 63. Sandoz (Novartis) Leuprolide Product
Table 64. Sandoz (Novartis) Revenue in Leuprolide Business (2019-2024) & (US$ Million)
Table 65. Sandoz (Novartis) Recent Development
Table 66. Sun Pharmaceutical Company Detail
Table 67. Sun Pharmaceutical Business Overview
Table 68. Sun Pharmaceutical Leuprolide Product
Table 69. Sun Pharmaceutical Revenue in Leuprolide Business (2019-2024) & (US$ Million)
Table 70. Sun Pharmaceutical Recent Development
Table 71. AbbVie Company Detail
Table 72. AbbVie Business Overview
Table 73. AbbVie Leuprolide Product
Table 74. AbbVie Revenue in Leuprolide Business (2019-2024) & (US$ Million)
Table 75. AbbVie Recent Development
Table 76. Bayer Company Detail
Table 77. Bayer Business Overview
Table 78. Bayer Leuprolide Product
Table 79. Bayer Revenue in Leuprolide Business (2019-2024) & (US$ Million)
Table 80. Bayer Recent Development
Table 81. Takeda Company Detail
Table 82. Takeda Business Overview
Table 83. Takeda Leuprolide Product
Table 84. Takeda Revenue in Leuprolide Business (2019-2024) & (US$ Million)
Table 85. Takeda Recent Development
Table 86. Beijing Boente Pharmaceutical Company Detail
Table 87. Beijing Boente Pharmaceutical Business Overview
Table 88. Beijing Boente Pharmaceutical Leuprolide Product
Table 89. Beijing Boente Pharmaceutical Revenue in Leuprolide Business (2019-2024) & (US$ Million)
Table 90. Beijing Boente Pharmaceutical Recent Development
Table 91. Livzon Pharmaceutical Company Detail
Table 92. Livzon Pharmaceutical Business Overview
Table 93. Livzon Pharmaceutical Leuprolide Product
Table 94. Livzon Pharmaceutical Revenue in Leuprolide Business (2019-2024) & (US$ Million)
Table 95. Livzon Pharmaceutical Recent Development
Table 96. Selleck Company Detail
Table 97. Selleck Business Overview
Table 98. Selleck Leuprolide Product
Table 99. Selleck Revenue in Leuprolide Business (2019-2024) & (US$ Million)
Table 100. Selleck Recent Development
Table 101. Hangzhou Peptide Biochemical Company Detail
Table 102. Hangzhou Peptide Biochemical Business Overview
Table 103. Hangzhou Peptide Biochemical Leuprolide Product
Table 104. Hangzhou Peptide Biochemical Revenue in Leuprolide Business (2019-2024) & (US$ Million)
Table 105. Hangzhou Peptide Biochemical Recent Development
Table 106. Chengdu Shenguo Biological Pharmaceutical Company Detail
Table 107. Chengdu Shenguo Biological Pharmaceutical Business Overview
Table 108. Chengdu Shenguo Biological Pharmaceutical Leuprolide Product
Table 109. Chengdu Shenguo Biological Pharmaceutical Revenue in Leuprolide Business (2019-2024) & (US$ Million)
Table 110. Chengdu Shenguo Biological Pharmaceutical Recent Development
Table 111. SciAnda Pharma Company Detail
Table 112. SciAnda Pharma Business Overview
Table 113. SciAnda Pharma Leuprolide Product
Table 114. SciAnda Pharma Revenue in Leuprolide Business (2019-2024) & (US$ Million)
Table 115. SciAnda Pharma Recent Development
Table 116. Daewoong Company Detail
Table 117. Daewoong Business Overview
Table 118. Daewoong Leuprolide Product
Table 119. Daewoong Revenue in Leuprolide Business (2019-2024) & (US$ Million)
Table 120. Daewoong Recent Development
Table 121. GP Pharm Company Detail
Table 122. GP Pharm Business Overview
Table 123. GP Pharm Leuprolide Product
Table 124. GP Pharm Revenue in Leuprolide Business (2019-2024) & (US$ Million)
Table 125. GP Pharm Recent Development
Table 126. Enteris BioPharma Company Detail
Table 127. Enteris BioPharma Business Overview
Table 128. Enteris BioPharma Leuprolide Product
Table 129. Enteris BioPharma Revenue in Leuprolide Business (2019-2024) & (US$ Million)
Table 130. Enteris BioPharma Recent Development
Table 131. Chong Kun Dang Company Detail
Table 132. Chong Kun Dang Business Overview
Table 133. Chong Kun Dang Leuprolide Product
Table 134. Chong Kun Dang Revenue in Leuprolide Business (2019-2024) & (US$ Million)
Table 135. Chong Kun Dang Recent Development
Table 136. Leadiant Biosciences Company Detail
Table 137. Leadiant Biosciences Business Overview
Table 138. Leadiant Biosciences Leuprolide Product
Table 139. Leadiant Biosciences Revenue in Leuprolide Business (2019-2024) & (US$ Million)
Table 140. Leadiant Biosciences Recent Development
Table 141. Hikma Pharmaceuticals Company Detail
Table 142. Hikma Pharmaceuticals Business Overview
Table 143. Hikma Pharmaceuticals Leuprolide Product
Table 144. Hikma Pharmaceuticals Revenue in Leuprolide Business (2019-2024) & (US$ Million)
Table 145. Hikma Pharmaceuticals Recent Development
Table 146. Lee Pharma Company Detail
Table 147. Lee Pharma Business Overview
Table 148. Lee Pharma Leuprolide Product
Table 149. Lee Pharma Revenue in Leuprolide Business (2019-2024) & (US$ Million)
Table 150. Lee Pharma Recent Development
Table 151. Hanall Company Detail
Table 152. Hanall Business Overview
Table 153. Hanall Leuprolide Product
Table 154. Hanall Revenue in Leuprolide Business (2019-2024) & (US$ Million)
Table 155. Hanall Recent Development
Table 156. Research Programs/Design for This Report
Table 157. Key Data Information from Secondary Sources
Table 158. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Leuprolide Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Leuprolide Market Share by Type: 2023 VS 2030
Figure 3. Subcutaneous Features
Figure 4. Topical Features
Figure 5. Global Leuprolide Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Leuprolide Market Share by Application: 2023 VS 2030
Figure 7. Breast Cancer Case Studies
Figure 8. Endometriosis Case Studies
Figure 9. Precocious Puberty Case Studies
Figure 10. Prostate Cancer Case Studies
Figure 11. Uterine Fibrosis Case Studies
Figure 12. Other Case Studies
Figure 13. Leuprolide Report Years Considered
Figure 14. Global Leuprolide Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global Leuprolide Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Leuprolide Market Share by Region: 2023 VS 2030
Figure 17. Global Leuprolide Market Share by Players in 2023
Figure 18. Global Top Leuprolide Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Leuprolide as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by Leuprolide Revenue in 2023
Figure 20. North America Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America Leuprolide Market Share by Country (2019-2030)
Figure 22. United States Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Leuprolide Market Share by Country (2019-2030)
Figure 26. Germany Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Leuprolide Market Share by Region (2019-2030)
Figure 34. China Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Japan Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. South Korea Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Southeast Asia Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. India Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Australia Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Leuprolide Market Share by Country (2019-2030)
Figure 42. Mexico Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Brazil Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Leuprolide Market Share by Country (2019-2030)
Figure 46. Turkey Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Saudi Arabia Leuprolide Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. TOLMAR PHARMACEUTICALS Revenue Growth Rate in Leuprolide Business (2019-2024)
Figure 49. Sanofi Revenue Growth Rate in Leuprolide Business (2019-2024)
Figure 50. Teva Revenue Growth Rate in Leuprolide Business (2019-2024)
Figure 51. Sandoz (Novartis) Revenue Growth Rate in Leuprolide Business (2019-2024)
Figure 52. Sun Pharmaceutical Revenue Growth Rate in Leuprolide Business (2019-2024)
Figure 53. AbbVie Revenue Growth Rate in Leuprolide Business (2019-2024)
Figure 54. Bayer Revenue Growth Rate in Leuprolide Business (2019-2024)
Figure 55. Takeda Revenue Growth Rate in Leuprolide Business (2019-2024)
Figure 56. Beijing Boente Pharmaceutical Revenue Growth Rate in Leuprolide Business (2019-2024)
Figure 57. Livzon Pharmaceutical Revenue Growth Rate in Leuprolide Business (2019-2024)
Figure 58. Selleck Revenue Growth Rate in Leuprolide Business (2019-2024)
Figure 59. Hangzhou Peptide Biochemical Revenue Growth Rate in Leuprolide Business (2019-2024)
Figure 60. Chengdu Shenguo Biological Pharmaceutical Revenue Growth Rate in Leuprolide Business (2019-2024)
Figure 61. SciAnda Pharma Revenue Growth Rate in Leuprolide Business (2019-2024)
Figure 62. Daewoong Revenue Growth Rate in Leuprolide Business (2019-2024)
Figure 63. GP Pharm Revenue Growth Rate in Leuprolide Business (2019-2024)
Figure 64. Enteris BioPharma Revenue Growth Rate in Leuprolide Business (2019-2024)
Figure 65. Chong Kun Dang Revenue Growth Rate in Leuprolide Business (2019-2024)
Figure 66. Leadiant Biosciences Revenue Growth Rate in Leuprolide Business (2019-2024)
Figure 67. Hikma Pharmaceuticals Revenue Growth Rate in Leuprolide Business (2019-2024)
Figure 68. Lee Pharma Revenue Growth Rate in Leuprolide Business (2019-2024)
Figure 69. Hanall Revenue Growth Rate in Leuprolide Business (2019-2024)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
